Last reviewed · How we verify
16mg，KB
KB is a small molecule drug that targets the mechanism of action of the drug.
KB is a small molecule drug that targets the mechanism of action of the drug. Used for Phase 2 clinical trials for KB are ongoing, but the specific indication is not publicly disclosed..
At a glance
| Generic name | 16mg，KB |
|---|---|
| Sponsor | Tianjin Chasesun Pharmaceutical Co., LTD |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
However, the exact mechanism of action of KB is not well understood at this time.
Approved indications
- Phase 2 clinical trials for KB are ongoing, but the specific indication is not publicly disclosed.
Common side effects
- Unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 16mg，KB CI brief — competitive landscape report
- 16mg，KB updates RSS · CI watch RSS
- Tianjin Chasesun Pharmaceutical Co., LTD portfolio CI